Aydogan, M. Et Al. 2023. THE OUTCOME OF SECONDARY AML PATIENTS WITH PRIOR BREAST CANCER UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IS AS GOOD AS DE NOVO AML. 49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation , (ELECTR NETWORK), 181-182.

Aydogan, M., Karakaya, B., Ermis, G. Y., Cengiz Seval, G., Bozdag, S. C., Toprak, S. K., ... Topçuoğlu, P.(2023). THE OUTCOME OF SECONDARY AML PATIENTS WITH PRIOR BREAST CANCER UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IS AS GOOD AS DE NOVO AML . 49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (pp.181-182). , ELECTR NETWORK

Aydogan, Merve Et Al. "THE OUTCOME OF SECONDARY AML PATIENTS WITH PRIOR BREAST CANCER UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IS AS GOOD AS DE NOVO AML," 49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 2023

Aydogan, Merve Et Al. "THE OUTCOME OF SECONDARY AML PATIENTS WITH PRIOR BREAST CANCER UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IS AS GOOD AS DE NOVO AML." 49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation , ELECTR NETWORK, pp.181-182, 2023

Aydogan, M. Et Al. (2023) . "THE OUTCOME OF SECONDARY AML PATIENTS WITH PRIOR BREAST CANCER UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IS AS GOOD AS DE NOVO AML." 49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation , ELECTR NETWORK, pp.181-182.

@conferencepaper{conferencepaper, author={Merve Aydogan Et Al. }, title={THE OUTCOME OF SECONDARY AML PATIENTS WITH PRIOR BREAST CANCER UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IS AS GOOD AS DE NOVO AML}, congress name={49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation}, city={}, country={ELECTR NETWORK}, year={2023}, pages={181-182} }